Serentis Ltd.

Serentis is a commercially focused, emerging biopharmaceutical company with a number of products in clinical trials. We operate an outsourcing model and have an established network of research and development partners. Our objective is to add maximum value to our projects by undertaking rapid and efficient product development. Projects are sourced from both internal research and innovation, and from licensing and acquisitions in order to maintain a sustainable, risk-balanced product portfolio. Internal research is focused on repositioning existing drugs and their templates in new disease areas and indications. Serentis optimises its products for target indications via both chemical modification and reformulations. This approach allows Serentis to establish clinical proof-of-principle early in the development of a project, and avoids the risk and cost associated with the initial development of new chemical entities. Projects target conditions characterised by clear unmet need and validated biological targets. Our partnering strategy is to license or acquire assets which are in, or close to, clinical development.